ASX:CVB
CurveBeam AI Limited
Location: Australia
Response Rate
0 of 4 questions answered
Rate Your
Company Satisfaction
Help us improve
FY24 saw 23 device purchase orders, with a quarterly breakdown showing steady growth. How confident is management about sustaining or accelerating this order volume in FY25, particularly in international markets?
The partnership with Stryker is crucial for distribution in the U.S. How does CurveBeam AI plan to address the challenges posed by group practices preferring single CT solutions for all lower extremity guides?
The enhanced HiRise™ received FDA clearance in July 2024 and is targeting submissions for AI-aided tools. What is the anticipated timeline for regulatory approval of these tools, and how critical are they to the company’s revenue growth?
The FY24 revenue decreased to A$6.5 million from A$8.1 million in FY23 and A$11.5 million pro forma for FY23. What steps is management taking to address this declining revenue trend?